The lack of a relationship between PIK3CA mutation status and 2-week/pre-Ki67% in all the data sets suggests that the presence of a PIK3CA mutation has limited, if any, impact on the likelihood of benefit from presurgical anastrozole treatment in patients with primary BC. This evidence concerns the gene PIK3CA and breast cancer.